Healthy Volunteers
Conditions
Interventions
investigational material(s)
Generic name etc : Evacetrapib (LY2484595)
INN of investigational material :
Therapeutic category code : 218 Agents for hyperlipidemias
Dosage and Administration for Inves
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Overtly healthy Japanese, as determined by medical history and physical examination - Have a body mass index (BMI) of 18.0 to 29.9 kg/m^2 - Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Exclusion criteria
Exclusion criteria: - Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study - Have an abnormal supine blood pressure as determined by the investigator - Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data - Are women who are pregnant or lactating - Have used or intend to use over-the-counter, prescription medications, or herbal medicine 14 days prior to enrollment and during the study - Have donated blood of more than 400 mL in the last 12 weeks (males) or in the last 16 weeks (females), or any blood donation (including apheresis) within the last 4 weeks - Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to abide by alcohol restrictions - Are participants who currently smoke more than 10 cigarettes per day or are unwilling to abide by smoking restrictions
Outcome results
None listed